Comparison of administration of single- and triple-course steroid pulse therapy combined with tonsillectomy for immunoglobulin A nephropathy

Kanao Watanabe-Kusunoki, MD, PhD, Daigo Nakazawa, MD, PhD,∗, Junkya Yamamoto, MD, PhD, Naoko Matsuoka, MD, Nobuharu Kaneshima, MD, Tasuku Nakagaki, MD, PhD, Rie Yamamoto, MD, Tomochika Maoka, MD, PhD, Sari Iwasaki, MD, PhD, Takahiro Tsuji, MD, PhD, Yuichiro Fukasawa, MD, PhD, Naoki Nishimoto, MD, PhD, Saori Nishio, MD, PhD, Tatsuya Atsumi, MD, PhD

Abstract
Immunoglobulin A nephropathy (IgAN) is a form of chronic glomerulonephritis that can cause end-stage renal disease. Recently, tonsillectomy combined with corticosteroid pulse (TSP) has been shown to be effective for achieving clinical remission and favorable renal outcome in patients with IgAN. However, the standard regimen of corticosteroid use in TSP has not been established. Herein, we compared the effect of single- or triple-course steroid pulse therapy combined with tonsillectomy in patients with IgAN.

This retrospective, observational cohort study included 122 patients with IgAN enrolled from January 2004 to December 2018 at 2 independent institutions. We divided the patients into 2 groups; single-course (TSP1: n = 70) and triple-course (TSP3: n = 52) of corticosteroid pulse therapy (1 course comprised 3 consecutive days’ infusion of 0.5 g methylprednisolone) combined with tonsillectomy. The primary outcome for renal survival was defined as the first occurrence of ≥30% decrease in estimated glomerular filtration rate from baseline. Secondary outcomes included the incidence of clinical remission and recurrence of the disease.

Regarding clinical parameters and findings at baseline, there were no significant differences between the 2 groups. The 8-years renal survival in the 2 groups was not significantly different according to Kaplan-Meier curves (TSP1: 82.5% vs TSP3: 69.2%, log-rank test P = .39). The cumulative incidence rates of remission of hematuria (94.4% vs 85.4%, P = .56) and clinical remission (85.0% vs 64.8%, P = .07) were comparable in both groups, while those of proteinuria showed higher rates in TSP1 than TSP3 (88.4% vs 65.4%, P = .02). The cumulative incidence of relapse of hematuria (5.6% vs 2.3%, P = .42) and proteinuria (7.1% vs 3.3%, P = .41) showed no significant differences in the 2 groups. Cox regression analyses showed that the number of courses of corticosteroid pulse therapy was not significantly associated with renal outcome (TSP1 vs TSP3; Hazard ratios 0.69, 95% confidence interval 0.29-1.64, P = .39).

The effect of single-course corticosteroid pulse therapy is not statistically, significantly different from triple-course in TSP protocol for improving renal outcome and preventing relapse in patients with IgAN. Single-course corticosteroid pulse therapy may become a treatment option for patients with IgAN.

Abbreviations: Alb = albumin, C3 = complement 3, CI = confidence intervals, CKD = chronic kidney disease, eGFR = estimated glomerular filtration rate, Hba1c = hemoglobin A1c, HPF = high power field, HR = hazard ratios, IgAN = immunoglobulin A nephropathy, RAS-i = renin-angiotensin system inhibitor, sCr = serum creatinine, TSP = tonsillectomy combined with corticosteroid pulse, TSP1 = tonsillectomy combined with single-course corticosteroid pulse therapy, TSP3 = tonsillectomy combined with triple-course corticosteroid pulse.

Keywords: immunoglobulin A nephropathy, relapse, remission, steroid pulse therapy, tonsillectomy

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received: 19 May 2021 / Received in final form: 28 August 2021 / Accepted: 28 October 2021
1. Introduction

Immunoglobulin A nephropathy (IgAN) is the most common form of primary chronic glomerulonephritis characterized by IgA glomerular deposition and mesangial proliferation. Most patients present with slow progression of the disease with microscopic hematuria and proteinuria. However, 20% to 40% of patients progress to end-stage renal disease within 20 years. IgAN is a complex multifactorial disease, which might be associated with continuous mucosal infection and impaired immune regulation, resulting in glomerular injury with the deposition of IgA1 immune complexes. Based on these assumptions, over the last few decades, various therapeutic interventions have been attempted on patients with IgAN. According to the Kidney Disease Improving Global Outcomes guidelines, the supportive care including blood pressure management with renin-angiotensin system inhibitor (RAS-i) and lifestyle modification is recommended for patients with IgAN as a first line. While, the immunosuppressive therapy is considered for patients with IgAN who are at high risk of progressive chronic kidney disease (CKD) despite maximal supportive care. Corticosteroids are key in the management of IgAN for reducing proteinuria and preventing end-stage renal disease. Tonsillectomy is also reportedly effective for patients with IgAN. A randomized controlled study showed that tonsillectomy exhibited considerable improvement in the time to reach the first remission, cumulative remission rate, duration of the first remission, and relapse rate for both hematuria and proteinuria, compared to the control group with supportive therapy alone. A recent large cohort study reported that tonsillectomy improved renal survival independent of the use of RAS-i and corticosteroid. Furthermore, tonsillectomy combined with corticosteroid therapy has additional effects toward achieving clinical remission. However, the ideal dosage of corticosteroid, when combined with tonsillectomy, remains controversial. According to the protocol described by Hotta et al., patients receive triple-course intravenous methylprednisolone pulse therapy of 0.5 g/d for 3 consecutive days within 6 months from the beginning of treatment, followed by oral prednisolone (0.6 mg/kg administered every other day). Oral prednisolone was tapered down by 5 mg every 8 weeks and discontinued within 1 year, by reference to the treatment regimen described by Hotta et al. In TSP3 group, the second and third timing of corticosteroid pulse was scheduled by the physician’s clinical decision within 6 months, including 3 consecutive days for 3 consecutive weeks or those bimonthly for 3 times. Tonsillectomy was performed before or within 1 year after corticosteroid administration.

2.2. Treatment protocol

Patients underwent single-course (TSP1) or triple-course (TSP3) intravenous methylprednisolone pulse therapy of 0.5 g/d for 3 consecutive days within 6 months from the beginning of treatment, followed by oral prednisolone (0.6 mg/kg administered every other day). Oral prednisolone was tapered down by 5 mg every 8 weeks and discontinued within 1 year, by reference to the treatment regimen described by Hotta et al. In TSP3 group, the second and third timing of corticosteroid pulse was scheduled by the physician’s clinical decision within 6 months, including 3 consecutive days for 3 consecutive weeks or those bimonthly for 3 times. Tonsillectomy was performed before or within 1 year after corticosteroid administration.

2.3. Evaluation of clinical and laboratory data

Laboratory data and clinical findings at the beginning of corticosteroid pulse administration were recorded as baseline. We included as follows: gender, age, body mass index, systolic and diastolic blood pressure, proteinuria, hematuria, sCr, estimated glomerular filtration rate (eGFR), stage of chronic kidney disease, clinical grade based on criteria of the Japanese Society of Nephrology (grade 1: proteinuria < 0.5 g/d, grade 2: eGFR ≥ 60 mL/min/1.73 m² and proteinuria ≥ 0.5 g/d, grade 3: eGFR < 60 mL/min and proteinuria ≥ 0.5 g/d), serum albumin (Alb), serum IgA, serum complement 3 (C3), IgA/C3 ratio, hemoglobin A1c, and administration of renin RAS-i at baseline. The number of urinary sediment red blood cells was scored as follows: <1/ high power field (HPF); 1, 1-4/ HPF; 2, 5-9/ HPF; 3, 10-19/ HPF; 4, 20-29/ HPF; 5, 30-49/ HPF; 6, 50-99/ HPF; 7, ≥ 100/ HPF; 8. eGFR was computed according to the equation previously reported. The following equation (modified from the Modification of Diet in Renal Disease equation) was used to estimate eGFR based on serum creatinine value: eGFR (mL/min/1.73 m²) = 194 × (serum creatinine [mg/dL]) − 1.094 × (age [years]) − 0.287 (× 0.739 if female). Histological grading was performed according to the Oxford classification and Clinical guides for immunoglobulin A nephropathy in Japan, third version (the fraction of the total number of glomeruli displaying active or chronic lesions are <25%: grade I, 25%-49.9%: grade II, 50%-74.9%: grade III, and ≥75%: grade IV).

2.4. Outcomes

The primary outcome was the occurrence of renal events, defined as the first occurrence of ≥30% decrease in eGFR from baseline. Secondary outcomes were the incidences of clinical remission, relapse and adverse events. Urinary remission was defined as cessation of hematuria (<5 RBC/HPF) or proteinuria (<0.3 g/gCr) 3 or more consecutive times or over
6 months, respectively. The cessation of both hematuria and proteinuria was defined as clinical remission. We also assessed the incidences of relapse among patients with urinary remission following TSP. Relapse was defined as reappearance of urinary abnormalities in 3 consecutive analyses.

2.5. Statistical analysis

To summarize baseline characteristics, we used mean ± standard deviation for continuous variables, and numbers and percentages (%) for categorical variables. We compared normally distributed (or non-parametric), categorical variables using unpaired Student t test and Pearson χ² test, respectively. The cumulative incidences of the decrease in eGFR, remission, and recurrence in the 2 groups were analyzed using the Kaplan-Meier method and compared using a Log-rank test. We used Cox proportional hazards regression models to evaluate the impacts of baseline factors on renal outcome (TSP1 vs TSP3, age over mean vs under mean, male vs female, eGFR < 60 vs ≥60, proteinuria ≥0.5 g/gCr vs <0.5 g/gCr, hematuria score ≥6 vs <6, H-grade ≥2 vs 1, alb over mean vs under mean and RAS-i vs no-RAS-i). All independent variables used in Cox regression analyses were categorical variables. The results of analyses were expressed as hazard ratios (HR) with 95% confidence intervals (CI). All analyses were performed using JMP Pro 14 (SAS Institute Inc, Tokyo, Japan), and GraphPad Prism 7 software (GraphPad, La Jolla, CA). Power calculations were based on a comparison of the 2 treatment groups using the Southwest Oncology Group statistical tools (Seattle, WA). Differences with P values of <.05 (bilateral) were considered significant.

3. Results

3.1. Patient characteristics

We enrolled 286 IgAN patients who underwent corticosteroid pulse therapy from 2004 to 2018. We excluded 3 patients whose renal biopsies were unavailable, 79 who were not followed-up for over 2 years, 23 who had received other corticosteroid protocols or immunosuppressants, 42 who did not undergo tonsillectomy, 9 who had a recurrence of the disease and received steroid therapy within 10 years, 1 on hemodialysis, and 7 complicated with other renal diseases. Among the remaining 122 patients, 70 underwent single-course steroid pulse therapy (TSP1), whereas 52 underwent triple-course steroid pulse therapy (TSP3) combined with tonsillectomy (Fig. 1).

The baseline characteristics of the 2 groups are shown in Table 1. There were no significant differences in gender, age, body mass index, systolic and diastolic blood pressure, IgA, C3, IgA/C3, hemoglobin A1c between the 2 groups. Mean levels of Alb were significantly higher in TSP1 (4.1 g/dL) than in TSP3 (3.7 g/dL). Mean levels of proteinuria (TSP1 vs TSP3: 0.75 vs 1.07 g/gCr), sCr (0.93 vs 0.86 mg/dL), eGFR (78.5 vs 76.2 mL/min/1.73 m²), the proportion of hematuria score over 6 (i.e. ≥30-49/HPF) (40.0% vs 44.2%), distribution of CKD stage and clinical grade (defined by Japanese Society of Nephrology), and the interval from renal biopsy had no significant difference between the 2 groups. The rate using RAS-i in TSP1 (30.0%) was higher than in TSP3 (13.5%). Histological grade was not significantly different between the 2 groups (Table 2).

**Figure 1.** Flow chart of patient selection. IgAN = immunoglobulin A nephropathy, TSP1 = tonsillectomy combined with single-course corticosteroid pulse, TSP3 = tonsillectomy combined with triple-course corticosteroid pulse.
Table 1

|                  | TSP1 (n=70) | TSP3 (n=52) | \( P \) value |
|------------------|-------------|-------------|--------------|
| Male             | 31 (44.3%)  | 16 (30.8%)  | .14          |
| Age (yrs)        | 36.1±12.2   | 36.0±11.2   | .97          |
| BMI (kg/m²)      | 22.0±3.5    | 21.4±3.4    | .34          |
| Interval from renal biopsy (yrs) | 1.6±4.1 | 0.6±1.4 | .06 |
| Observation period (yrs) | 4.8±1.8 | 5.4±1.8 | .06 |
| Systolic BP (mm Hg) | 118.3±15.7 | 116.9±15.0 | .64 |
| Diastolic BP (mm Hg) | 74.0±11.4 | 74.5±13.3 | .85 |
| Hematia score ≥6 | 28 (40.0%)  | 23 (44.2%)  | .71          |
| Proteinuria (g/gCr) | 0.75±0.83 | 1.07±1.18 | .08 |
| sCr (mg/dL)      | 0.93±0.48   | 0.86±0.33   | .38          |
| IgA (mg/dL)      | 78.5±31.2   | 76.2±24.6   | .67          |
| IgA/C3 ratio     | 46 (65.7%)  | 38 (73.1%)  | .38          |
| Albumin (g/dL)   | 20 (30.6%)  | 16 (30.8%)  | .14          |
| Grade 1          | 20 (28.6%)  | 16 (30.8%)  | .14          |
| Grade 2          | 15 (21.4%)  | 16 (30.8%)  | .14          |
| Grade 3          | 5 (7.1%)    | 4 (7.7%)    | .56          |
| Grade 4          | 2 (2.9%)    | 1 (1.9%)    | .56          |
| Grade 5          | 1 (1.4%)    | 0 (0)       | .56          |

Data are mean±SD or number (%).

Ab = albumin, BMI = body mass index, BP = blood pressure, C3 = complement 3, CKD = chronic kidney disease, eGFR = estimated glomerular filtration rate, HbA1c = hemoglobin A1c, IgA = immunoglobulin A, RAS-i = renin-angiotensin system inhibitor, sCr = serum creatinine.

3.2. Outcomes of renal survival and clinical remission

Eight-years renal survival (defined as ≥30% decrease in eGFR from baseline) was 82.5% and 69.2%, in TSP1 and TSP3, respectively, with a statistical power of over 90% (2-sided, \( \alpha = 0.05 \)); the difference was not significant (Fig. 2). The cumulative incidences of remission of hematuria, proteinuria, and both (clinical remission) in TSP1 and TSP3 groups were 94.4% and 85.4%, 88.4% and 65.4%, and 85.0% and 64.8%, respectively. While there were no significant differences between the 2 groups in the cumulative incidences of remission of hematuria and clinical remission, those of proteinuria showed higher rates in TSP1 than TSP3 (Fig. 3). Among patients who achieved urination remission, the mean intervals from baseline to remission of hematuria were 0.91 years in TSP1 and 0.67 years in TSP3, and those of proteinuria were 0.52 years in TSP1 and 0.44 years in TSP3. Regarding the clinical course, the levels of proteinuria in the 2 groups showed no significant differences within 12 months. The levels of proteinuria were significantly lower in TSP1 than in TSP3 at 2, 4, 6, 8, and 12 months (Fig. 4).

We analyzed the relapse rate among patients who achieved urinary remission after undergoing TSP1 or TSP3. The number of patients who achieved remission of hematuria and proteinuria was 56 and 58 in TSP1, and 44 and 34 in TSP3, respectively. The cumulative incidences of relapse of hematuria and proteinuria were 5.6% and 7.1% in TSP1, and 2.3% and 3.3% in TSP3, respectively. Overall, there were no significant differences between the 2 groups (Fig. 5). Among patients who experienced urinary relapse, the mean duration from remission to relapse of hematuria and proteinuria was 0.79 years and 1.11 years in TSP1, and 0.75 years and 2.45 years in TSP3, respectively. All patients with relapse underwent additional treatment.

During the TSP treatment, no serious adverse event that required hospitalization occurred in the 2 groups.

Table 2

|                  | TSP1 (n=63) | TSP3 (n=45) | \( P \) value |
|------------------|-------------|-------------|--------------|
| Oxford classification | n=27 | n=31 | .97          |
| Mesangial sclerosis (M1) | 5 (18.5%) | 5 (16.1%) | 1.00 |
| Segmental glomerulosclerosis (S1) | 16 (69.3%) | 19 (61.3%) | 1.00 |
| Endocapillary hypercellularity (E1) | 6 (22.2%) | 10 (32.3%) | .56 |
| Tubular atrophy/interstitial fibrosis (I) | .68 |
| T1                | 19 (24.6%)  | 17 (37.8%)  | .06 |
| T2                | 5 (6.3%)    | 0 (0)       | .56          |
| Histological grade (Japanese Society of Nephrology) | n=63 | n=45 | .50 |
| Grade 1           | 32 (50.0%)  | 15 (33.3%)  | .08 |
| Grade 2           | 20 (31.8%)  | 17 (37.8%)  | .08 |
| Grade 3           | 9 (14.3%)   | 11 (24.4%)  | .08 |
| Grade 4           | 2 (3.2%)    | 2 (4.4%)    | .08 |

Data are number (%). TSP = tonsillectomy combined with corticosteroid pulse.

3.3. Associated baseline factors contributing to renal outcome

We used Cox proportional hazards regression analysis to identify the factors associated with renal outcome (≥30% decrease in eGFR from baseline) among all patients who underwent TSP treatment (Table 3). Univariate Cox regression analysis revealed that age, gender, number of courses of corticosteroid pulse therapy (TSP1 vs TSP3; HR 0.69, 95% CI 0.29-1.64, \( P = .39 \)), severity of histological grade, levels of eGFR, proteinuria, hematuria, and RAS-i use (RAS-i vs no-RAS-i; HR 1.80, 95% CI 0.68-4.34, \( P = .22 \)) did not influence renal outcome.

4. Discussion

In this study, we compared the efficacies of single- and triple-course corticosteroid pulse therapy combined with tonsillectomy in patients...
with IgAN. Our findings demonstrated that a single-course protocol (TSP1) achieved favorable outcomes, including preservation of renal function and induction of urinary remission, not significantly different from the triple-course protocol (TSP3) with adequate statistical power. In addition, TSP1 and TSP3 showed comparable efficacy to prevent relapse after remission. These results indicate that the TSP1 protocol may improve the prognosis of patients with IgAN as the conventional TSP protocol (TSP3).

The pathogenesis of IgAN is characterized by the mesangial deposition of IgA1 immune complexes, which is associated

Figure 3. Cumulative incidence of remission of hematuria, proteinuria, and both (clinical remission) in TSP1 and TSP3. (A) Cumulative incidence of remission of proteinuria (less than 0.3 g/gCr in 3 consecutive analyses or over 6 mo) in the 2 groups. (B) Cumulative incidence of remission of hematuria (less than 5 RBC/HPF in 3 consecutive analyses or over 6 mo) in the 2 groups. (C) Cumulative incidence of clinical remission (remission of both hematuria and proteinuria) in the 2 groups. Comparisons were made using the Kaplan-Meier method and log rank test. Statistically significant differences between the groups are indicated with \( P < .05 \). HPF = high power field; TSP1 = tonsillectomy combined with single-course corticosteroid pulse, TSP3 = tonsillectomy combined with triple-course corticosteroid pulse.

Figure 4. Serial changes of proteinuria and hematuria in TSP1 and TSP3. (A) The levels of proteinuria (g/gCr) in the 2 groups were described from the baseline to 12 mo. (B) The hematuria scores in the 2 groups were described from the baseline to 12 mo. Data represent the mean ± standard deviation. Comparisons were made using an unpaired Student t test for each month. Statistically significant differences between the groups are indicated with asterisks, \( *P < .05 \). TSP1 = tonsillectomy combined with single-course corticosteroid pulse, TSP3 = tonsillectomy combined with triple-course corticosteroid pulse.
with a disordered mucosal-bone marrow immunity and initiates glomerular injury leading to glomerulosclerosis and tubulointerstitial fibrosis.\[2,20\] Considering these pathologies, tonsillectomy might be useful for regulating the upstream of the disease via reducing aberrant IgA1, whereas corticosteroid therapy has the potential to ameliorate renal injury, the downstream of IgAN pathogenesis, by suppressing glomerular inflammation and fibrosis. Although either single treatment of corticosteroid or tonsillectomy has been reported to have insufficient or contradictory results,\[21-24\] the combined tonsillectomy and corticosteroid pulse therapy introduced by Hotta et al\[9\] showed favorable outcomes. A prospective controlled study showed that the combined tonsillectomy and corticosteroid pulse therapy was superior to steroid pulse monotherapy in inducing clinical remission and preserving renal function via the maintenance of urinary remission.\[24\] Therefore, the combined therapy has since been widely used in Japan. Recently, a large retrospective cohort study demonstrated favorable long-term outcomes of tonsillectomy independent of the use of corticosteroid and RAS-i\[8\] and the indication of TSP treatment for patients with IgAN has been accepted.

However, the dosage of corticosteroids remains controversial, thus an optimal regimen of corticosteroid administration in TSP protocol is needed for avoiding excessive adverse effects.\[11,12,25\]

Some reports focused on the number of courses of corticosteroid pulse therapy combined with tonsillectomy. Kaneko et al\[26\] reported that single-course corticosteroid pulse therapy combined with mizoribine was effective for preserving renal function compared to triple-course corticosteroid pulse therapy. The study indicated that the addition of mizoribine might reduce the required number of courses of corticosteroid pulse therapy. Watanabe et al\[27\] showed that TSP3 had an effect to rapidly induce remission of hematuria compared to TSP1, although there was no significant difference in the clinical remission rates between the 2 groups, which was consistent with our study. Their study was conducted over a short term and did not assess renal outcome. Takada et al\[28\] reported that tonsillectomy with triple-course corticosteroid pulse therapy had a relation to better renal prognosis compared to twice or fewer courses of corticosteroid pulse therapy. However, the analysis did not directly assess the differences in efficacies between TSP1 and TSP3. Furthermore, the timing of corticosteroid pulses was not uniformed. Their study settings were therefore different from ours.

In the present study, we directly evaluated the clinical remission and renal prognosis of TSP1 and TSP3 therapy in which the corticosteroid pulse was conducted within a limited period. The primary outcome for renal survival and the incidence of clinical remission showed no significant difference in the 2 groups with adequate statistical power (i.e. >90%, 2-sided, α = 0.05), implying that TSP1 protocol might be sufficient for effective regulation of IgAN in certain cases. Of note, we investigated the relapse rate following TSP treatment. The relapse rate after corticosteroid monotherapy was roughly 20% to 50%,\[29\] while the rate after tonsillectomy alone was around 40% at 2 years after remission, according to the previous reports. In our study, TSP3, and notably TSP1, showed lower relapse rates compared to these reports. This preventive effect can be explained by the mechanisms of tonsillectomy as reducing the chance of developing chronic tonsillitis, decreasing the production of pathogenic IgA,\[7\] and increasing CD4+ CD25+ Treg cells.\[30\] Furthermore, corticosteroid pulse therapy can reduce IgA1 production via inducing apoptosis of memory T lymphocytes.\[31\] Based on these therapeutic mechanisms, the combination of tonsillectomy and even only a single-course corticosteroid pulse is efficient to reset the vicious cycle of the mucosa-bone marrow

![Figure 5. Cumulative incidence of relapse of hematuria and proteinuria in TSP1 and TSP3. (A) Cumulative incidence of relapse of proteinuria (more than 0.3 g/gCr in 3 consecutive analyses, followed by additional treatment to re-induce remission) in the 2 groups. (B) Cumulative incidence of relapse of hematuria (more than 5 RBC/HPF in 3 consecutive analyses, followed by additional treatment to re-induce remission) in the 2 groups. Comparisons were made using the Kaplan-Meier method and log rank test. Statistically significant differences between the groups are indicated with P<.05. HPF = high power field, TSP1 = tonsillectomy combined with single-course corticosteroid pulse, TSP3 = tonsillectomy combined with triple-course corticosteroid pulse.](image)
axis, resulting in the prevention of relapse. This corticosteroid-minimized therapy can contribute to shorter hospitalization periods. Moreover, the smaller number of corticosteroid pulses might prevent side effects including osteoporosis,[32] hyperglycemia,[13] and psychosis.[14] Although randomized controlled clinical trials are needed to confirm the effectiveness of the therapy, our report indicates the possibility of TSP1 treatment as an effective and safe treatment strategy for IgAN.

There are some limitations in this study. First, this is a retrospective cohort study with a limited sample size, which may have led to bias. Importantly, the selection of the number of corticosteroid pulse therapy was determined by physicians. In fact, TSP3 group at baseline had hypo-albuminemia compared to TSP1, which may underestimate the superiority of TSP3. However, there was no significant difference in the levels of proteinuria and renal function at baseline between the 2 groups. Second, the efficacy of TSP1 in cases with severe IgAN, who rapidly progress to renal dysfunction with high disease activity, is uncertain because the majority of enrolled IgAN patients in this study presented with mild activity and chronic course. Third, we recorded only serious adverse events related to TSP. Additional prospective cohort studies are required to further validate the efficacies and disadvantages of single-course corticosteroid pulse administration combined with tonsillectomy.

5. Conclusions
Our study demonstrated that single-course corticosteroid pulse administration combined with tonsillectomy achieved favorable outcomes, including preservation of renal function and induction of urinary remission, and prevented relapse, as triple-course protocol.

Acknowledgments
We thank all the staff members at Hokkaido University Hospital and NTT Medical Center Sapporo who were taking care of patients. We thank Richard Robins, PhD, from Edanz Group (https://en-author-services.edanzgroup.com/) for editing a draft of this manuscript.

Author contributions
KW-K, DN, and NK contributed to the conception and design of the work. KW-K and DN wrote and summarized the manuscript. KW-K, DN, JY, NM, NK, TN, NY, TM, and SN managed and followed up the patients’ care. SI, TT, and YF made the pathological diagnosis. KW-K, DN, and NN made statistical analyses. KW-K, DN, JY, TN, SI, TT, SN, and TA revised the manuscript critically. All authors have read and approved the manuscript.

Conceptualization: Kanako Watanabe-Kusunoki, Daigo Nakazawa.

Formal analysis: Kanako Watanabe-Kusunoki, Naoki Nishimoto.

Investigation: Kanako Watanabe-Kusunoki, Junya Yamamoto, Sari Iwasaki, Takahiro Tsuji, Yuichiro Fukasawa, Saori Nishio.

Resources: Tasuku Nakagaki, Rie Yamamoto, Tomochika Maoka.

Validation: Junya Yamamoto.

Writing – original draft: Kanako Watanabe-Kusunoki.

References
[1] Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis 1997;29:526–32.
[2] Moldoveanu Z, Wyatt RJ, Lee JY, et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 2007;71:1148–54.
[3] Komatsu H, Fujimoto S, Hara S, et al. Recent therapeutic strategies improve renal outcome in patients with IgA nephropathy. Am J Nephrol 2009;30:19–25.
[4] Pozzi C, Bolasco P, Fogazzi G, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 1999;353:883–7.
[5] Akagi H, Kosaka M, Hattori K, et al. Long-term results of tonsillectomy as a treatment for IgA nephropathy. Acta Otolaryngol Suppl 2004;555:38–42.
[6] Komatsu H, Fujimoto S, Kikuchi M, Sato Y, Kitamura K. Tonsillectomy delays progression of advanced IgA nephropathy to end-stage kidney disease. Ren Fail 2012;34:448–53.
[7] Yang D, He I, Peng X, et al. The efficacy of tonsillectomy on clinical remission and relapse in patients with IgA nephropathy: a randomized controlled trial. Ren Fail 2016;38:242–9.
[8] Hirano K, Matsuizaki K, Yasuda T, et al. Association between tonsillectomy and outcomes in patients with immunoglobulin A nephropathy. JAMA Netw Open 2019;2:e194772.
[9] Hotta O, Miyazaki M, Furuta T, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis 2001;38:736–43.
[10] Kawamura T, Yoshimura M, Miyazaki Y, et al. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant 2014;29:1546–53.
[11] Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015;373:2225–36.
[12] Lv J, Zhang H, Wong MG, et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 2017;318:432–42.
[13] Matsuoi S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982–92.
[14] Cattrfan DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009;76:534–45.
[15] Rebholz CM, Grams ME, Matsushita K, Selvin E, Coresh J. Change in novel filtration markers and risk of ESRD. Am J Kidney Dis 2015;66:47–54.
[16] Matsushita K, Chen J, Sang Y, et al. Risk of end-stage renal disease in Japanese patients with chronic kidney disease increases proportionately to decline in estimated glomerular filtration rate. Kidney Int 2016;90:1109–14.
[17] Suzuki Y, Matsuzaki K, Suzuki H, et al. Proposal of remission criteria for IgA nephropathy. Clin Exp Nephrol 2004;8:157–63.
[18] Ohya M, Otani H, Minami Y, et al. Tonsillectomy with steroid pulse therapy has more effect on the relapse rate than steroid pulse monotherapy in IgA nephropathy patients. Clin Nephrol 2013;80:47–52.
[19] Oortwijn BD, Rastaldi MP, Roos A, Martinolli D, Daha MR, van Kooten C. Demonstration of secretory IgA in kidneys of patients with IgA nephropathy. Nephrol Dial Transplant 2007;22:3191–5.
[20] Itoh A, Iwashe H, Takatani T, et al. Tonsillar IgA1 as a possible source of hypoglycosylated IgA1 in the serum of IgA nephropathy patients. Nephrol Dial Transplant 2003;18:1108–14.
[21] Rasche FM, Schwarz A, Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrol 1999;51:147–52.
[22] Piccoli A, Codognotto M, Tabbii MG, Favaro E, Rossi B. Influence of tonsillectomy on the progression of mesangio proliferative glomerulonephritis. Nephrol Dial Transplant 2010;25:2583–9.
[23] Pozzi C. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004;15:54–63.
[24] Komatsu H, Fujimoto S, Hara S, Sato Y, Yamada K, Kitamura K. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol 2008;3:1301–7.
van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000;39:1383–9.

Kaneko T, Arai M, Ikeda M, et al. Comparison of immunosuppressive therapies for IgA nephropathy after tonsillectomy: three-course versus one-course steroid pulse combined with mizoribine. Int Urol Nephrol 2015;47:1823–30.

Watanabe H, Goto S, Kondo D, et al. Comparison of methods of steroid administration combined with tonsillectomy for IgA nephropathy patients. Clin Exp Nephrol 2017;21:257–65.

Takada D, Hoshino J, Fujii T, et al. Association between renal outcome and the number of steroid pulse therapies after tonsillectomy in patients with IgA nephropathy. Clin Exp Nephrol 2019;23:335–41.

Laranjinha I, Matias P, Cassis J, et al. IGA nephropathy - are intravenous steroid pulses more effective than oral steroids in relapse prevention? Nefrologia 2018;38:355–60.

Huang H, Sun W, Liang Y, et al. CD4 (+)CD 25 (+)Treg cells and IgA nephropathy patients with tonsillectomy: a clinical and pathological study. Int Urol Nephrol 2014;46:2361–9.

Hotta O. Use of corticosteroids, other immunosuppressive therapies, and tonsillectomy in the treatment of IgA nephropathy. Semin Nephrol 2004;24:244–55.

Haugeberg G, Griffiths B, Sokoll KB, Emery P. Bone loss in patients treated with pulses of methylprednisolone is not negligible: a short term prospective observational study. Ann Rheum Dis 2004;63:940–4.

Tamez-Perez HE, Quintanilla-Flores DL, Rodriguez-Gutierrez R, Gonzalez-Gonzalez JG, Tamez-Pena AL. Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. World J Diabetes 2015;6:1073–81.

Hari P, Srivastava RN. Pulse corticosteroid therapy with methylprednisolone or dexamethasone. Indian J Pediatr 1998;65:557–60.